GLP-1 receptor agonists are gaining traction in addiction treatment, though the lack of FDA approval and long-term data continues to limit widespread adoption, Mo Sarhan, MD, medical director of addiction medicine for Delray Beach, Fla.-based Caron Treatment Centers, told Becker’s.…
GLP-1s
New Haven, Conn.-based Yale researchers are studying whether GLP-1 drugs may extend beyond diabetes and obesity treatment to address addiction, NBC Connecticut reported March 27. Rajita Sinha, PhD, director of the Yale Interdisciplinary Stress Center, studied semaglutide in people with…
The American Dental Association has updated patient health history forms to include a mental health screening question and a prompt about GLP-1 receptor agonists. The ADA Council on Dental Practice approved the changes in January, according to a March 24…